20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

The Science Behind ODM-201: A Potent AR Inhibitor for Oncology

The intricate science behind effective cancer therapeutics is constantly evolving, with a particular focus on overcoming drug resistance. In the realm of prostate cancer, the androgen receptor (AR) signaling pathway remains a central target, even in castration-resistant forms of the disease. ODM-201 (CAS: 1297538-32-9) stands out as a significant development in this field, representing a new generation of AR inhibitors. As a leading manufacturer and supplier of pharmaceutical intermediates in China, we provide the high-quality compounds that fuel such scientific breakthroughs.

ODM-201 operates through a potent AR antagonism mechanism. Its binding affinity to the androgen receptor is notably high, and crucially, it demonstrates superior performance against AR mutations that commonly emerge in response to existing anti-androgen therapies. Mutations like F876L, which render other drugs less effective, are potently antagonized by ODM-201. This makes it an indispensable pharmaceutical intermediate for research focused on developing therapies that can overcome acquired resistance in castration-resistant prostate cancer (CRPC).

The scientific profile of ODM-201 also includes a favorable safety and tolerability aspect. Its negligible brain penetration is a key differentiator, suggesting a reduced likelihood of central nervous system side effects compared to some earlier AR inhibitors. This characteristic is vital for patient compliance and overall treatment success. The preclinical data consistently points towards a strong therapeutic index, positioning ODM-201 as a compound of considerable interest for clinical development.

For researchers and pharmaceutical developers, understanding the scientific merit and sourcing capabilities of compounds like ODM-201 is crucial. We are committed to supplying this advanced pharmaceutical intermediate with uncompromising quality and competitive pricing, directly from our manufacturing facilities in China. If your work involves oncology research, particularly in prostate cancer, and you are looking to buy ODM-201, we encourage you to reach out. Let us be your trusted partner in accessing this scientifically significant compound.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Exploring ODM-201 in Castration-Resistant Prostate Cancer (CRPC) Treatment

Next: Choosing Halogen-Free Flame Retardants: A Guide for PA Formulators

All Rights Reserved